Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere
- PMID: 20545521
- DOI: 10.3109/03639041003677780
Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere
Erratum in
- Drug Dev Ind Pharm. 2014 May;40(5):699
Abstract
Objective: The objective of this study was to prepare a novel gastric mucoadhesive sustained-release acyclovir (AV)-resinate microsphere.
Methods: First, AV absorption ratio was quantified in a rat gastrointestinal (GI) tract model. AV-resinate was prepared by bath method and used as cores to prepare microspheres by an emulsion solvent diffusion technique with carbopol 934 as coating material. GI transit test of the prepared microspheres was carried out in rats and beagle dogs, followed by the in vivo bioavailability evaluation of the microspheres in beagle dogs.
Results: The AV absorption ratio in different segments of rat's GI track for 3 hours was as following: stomach 9.46 +/- 0.62%, duodenum 20.22 +/- 1.50%, jejunum 15.7 +/- 1.33%, ileum 9.15 +/- 1.01%, and colon 4.59 +/- 0.48%. These results showed that AV was mainly absorbed in the stomach and upper intestine. The average diameter of the microspheres was 115.3 microm. The microspheres had a drug content of 33.3 +/- 0.7% (w/w) and a sustained-release profile for 12 hours in vitro. The mucoadhesive test in rats and beagle dogs showed that most of the microspheres were retained in the stomach 6 hours after oral administration. The in vivo pharmacokinetics test revealed that the microsphere and reference (AV tablets) preparations have no significant difference for C(max). The t(max) has increased from 2.33 hours (reference) to 5 hours (test). Meanwhile, the relative bioavailability of AV microspheres was 145%.
Conclusion: A novel AV-resinate microsphere was prepared. The microspheres were proved to be gastric mucoadhesive and sustained-release with higher bioavailability.
Similar articles
-
Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability.Int J Pharm. 2009 Aug 13;378(1-2):30-6. doi: 10.1016/j.ijpharm.2009.05.025. Epub 2009 May 22. Int J Pharm. 2009. PMID: 19465102
-
Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.AAPS J. 2008 Jun;10(2):322-30. doi: 10.1208/s12248-008-9039-2. Epub 2008 Jun 4. AAPS J. 2008. PMID: 18523891 Free PMC article.
-
Gastroretentive drug delivery system of acyclovir-loaded alginate mucoadhesive microspheres: formulation and evaluation.Drug Deliv. 2011 May;18(4):255-64. doi: 10.3109/10717544.2010.536270. Epub 2010 Nov 26. Drug Deliv. 2011. PMID: 21110695
-
Gastroretentive Formulations for Improving Oral Bioavailability of Drugs-Focus on Microspheres and their Production.Curr Drug Deliv. 2016;13(5):646-61. doi: 10.2174/1567201812666151012113357. Curr Drug Deliv. 2016. PMID: 26456212 Review.
-
Floating microspheres: to prolong the gastric retention time in stomach.Curr Drug Deliv. 2012 May;9(3):315-24. doi: 10.2174/156720112800389061. Curr Drug Deliv. 2012. PMID: 22023206 Review.
Cited by
-
Critical Review of Synthesis, Toxicology and Detection of Acyclovir.Molecules. 2021 Oct 29;26(21):6566. doi: 10.3390/molecules26216566. Molecules. 2021. PMID: 34770975 Free PMC article. Review.
-
Statistical Design of Experiments on Fabrication of Bilayer Tablet of Narrow Absorption Window Drug: Development and In vitro characterisation.Indian J Pharm Sci. 2012 Jul;74(4):302-11. doi: 10.4103/0250-474X.107049. Indian J Pharm Sci. 2012. PMID: 23626385 Free PMC article.
-
Development of a gastroretentive delivery system for acyclovir by 3D printing technology and its in vivo pharmacokinetic evaluation in Beagle dogs.PLoS One. 2019 May 15;14(5):e0216875. doi: 10.1371/journal.pone.0216875. eCollection 2019. PLoS One. 2019. PMID: 31091273 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources